Targeting FGFR for rare pediatric diseases and cancer.

QED Therapeutics is targeting FGFR for patients with fusion-driven cancers and pediatric skeletal dysplasias.


Fibroblast growth factor receptors or FGFRs, are tyrokine kinase receptors on the surface of cells that link growth factor signalling with the downstream PI3K/AKT and MAPK pathways to regulate cellular proliferation and survival. The FGFR family has four members (encoded by the FGFR1-4 genes).

Overactivity of these pathways are critical contributors to many forms of cancers, most notably cholangiocarcinoma (bile duct cancer) and urothelial carcinoma (bladder cancer). FGFR2 fusions are present in 13% of cholangiocarcinomas, and FGFR3 mutations are present in 64% of non-muscle invasive urothelial carcinomas.

In achondroplasia, activating mutations in FGFR3 suppress proliferation and maturation of growth plate chondrocytes, leading to shortened bones. Complications can be severe, with an increased risk of death during infancy and the potential for compressed bone formation that can lead to nerve compression. Achondroplasia affects one out of every 20,000 live births.


Infigratinib (BGJ398) is a best-in-class, FGFR-selective, orally-administered investigational new drug in clinical development for the treatment of patients with FGFR-driven cancers. QED Therapeutics acquired the worldwide rights to infigratinib from Novartis for use in all applications and will develop the compound as a treatment for multiple FGFR-driven diseases, including cancers and achondroplasia.

Infigratinib is currently under study in a Phase 2 trial for the treatment of chemotherapy-refractory cholangiocarcinoma (bile duct cancer) with FGFR-fusions. In an early analysis of 63 patients in the ongoing trial, infigratinib demonstrated a 30.2% overall response rate. Of the subset of patients with FGFR2 fusions, there was a 39.6% overall response rate. To date, over 350 patients have been treated with infigratinib in numerous clinical trials. For more information about infigratinib clinical trials, please visit

For information on the clinical trial currently enrolling in cholangiocarcinoma, please email

In addition to its clinical data in FGFR-driven cancer, infigratinib has demonstrated potential in pediatric skeletal dysplasias, including achondroplasia. In the early work published in the Journal of Clinical Investigation, researchers demonstrated that low doses of infigratinib corrected pathological hallmarks of achondroplasia in mouse models. Importantly, by treating the disease at its source, inigratinib demonstrated greater than 2x improvement over any previously tested intervention for achondroplasia.

About Us

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.


BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source. Founded in 2015 by a team of industry veterans, the company has built a robust portfolio of fifteen transformative assets, each housed in its own subsidiary, ranging from pre-clinical to late stage development in multiple therapeutic areas including oncology, cardiology, dermatology and endocrinology. The company’s focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines.


One Ferry Building
Suite 220
San Francisco, CA 94111



© 2018 QED Therapeutics